Ingavirin

Summary

Ingavirin (CHEMBL4297291) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 5
• Chemistry: 225.24 Da · C10H15N3O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4297291
Name	Ingavirin
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	9942657
Molecular formula	C10H15N3O3
Molecular weight	225.24
InChIKey	KZIMLUFVKJLCCH-UHFFFAOYSA-N

SMILES: C1=C(NC=N1)CCNC(=O)CCCC(=O)O

IUPAC name: 5-[2-(1H-imidazol-5-yl)ethylamino]-5-oxopentanoic acid

Also known as: Imidazolyl ethanamide pentandioic acid, Ingamine, Ingavirin, INGAVIRIN

Patent coverage: 84 distinct patent families (219 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 203 (93%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 5.

Phase distribution

Phase	Trials
PHASE3	3
PHASE4	1
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03154515	PHASE4	COMPLETED	Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults
NCT02644018	PHASE3	COMPLETED	Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Patients 3-6 y.o.
NCT03191097	PHASE3	COMPLETED	Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.
NCT03206346	PHASE3	COMPLETED	Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.
NCT07420985	PHASE2	RECRUITING	Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) at Different Doses in Subjects With Influenza and Other Acute Respiratory Viral Infections.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).